BiotechTube

linezolid + vancomycin

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Febrile Neutropenia

Conditions

Febrile Neutropenia

Trial Timeline

Nov 1, 2001 → Nov 1, 2002

NCT ID
NCT00035425

About linezolid + vancomycin

linezolid + vancomycin is a phase 3 stage product being developed by Pfizer for Febrile Neutropenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00035425. Target conditions include Febrile Neutropenia.

What happened to similar drugs?

4 of 7 similar drugs in Febrile Neutropenia were approved

Approved (4) Terminated (4) Active (1)
✅Imipenem + ImipenemMerckApproved
✅Ceftolozane-Tazobactam + MeropenemMerckApproved
✅Ceftolozane-tazobactam IVMerckApproved
✅Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®)Gilead SciencesApproved
❌HHPG-19K InjectionJiangsu Hengrui MedicinePhase 3
❌Daptomycin + DaptomycinMerckPhase 3
🔄ciprofloxacin + cefepimeBayerPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT01561469Pre-clinicalCompleted
NCT00087490ApprovedCompleted
NCT00035425Phase 3Completed

Competing Products

8 competing products in Febrile Neutropenia

See all competitors
ProductCompanyStageHype Score
HHPG-19K InjectionJiangsu Hengrui MedicinePhase 3
32
Imipenem + ImipenemMerckApproved
43
Ceftolozane-Tazobactam + MeropenemMerckApproved
50
Ceftolozane-tazobactam IVMerckApproved
35
Daptomycin + DaptomycinMerckPhase 3
32
Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®)Gilead SciencesApproved
35
Antibacterial agent for the treatment of febrile neutropeniaPfizerPre-clinical
26
ciprofloxacin + cefepimeBayerPhase 3
37